Why Did Kairos Pharma Plunge 13.05% Despite Positive Drug Data?

On June 5, 2025, Kairos Pharma's stock price experienced a significant drop of 13.05% in pre-market trading, reflecting a notable decline in investor sentiment.

Kairos Pharma recently presented promising data on its investigational cancer drug KROS101 at the American Society of Clinical Oncology (ASCO) conference. This development has garnered attention from analysts, with Maxim Group maintaining a Buy rating on the stock and setting a price target of $12.00. The positive preclinical data for KROS101 has been highlighted as a key driver for the Buy rating, indicating potential for future growth and investor interest.

Despite the recent volatility, Kairos Pharma's stock has seen significant trading volume, with 2.82 million shares traded on a single day. This unusual volume suggests heightened market interest and potential for further price movements. The company's market capitalization stands at $9.91 million, positioning it as a clinical-stage biopharmaceutical player with promising developments in oncology.